ATE519762T1 - Benzazepinverbindungen mit affinität für den dopamin-d3-rezeptor und deren verwendung - Google Patents
Benzazepinverbindungen mit affinität für den dopamin-d3-rezeptor und deren verwendungInfo
- Publication number
- ATE519762T1 ATE519762T1 AT05756061T AT05756061T ATE519762T1 AT E519762 T1 ATE519762 T1 AT E519762T1 AT 05756061 T AT05756061 T AT 05756061T AT 05756061 T AT05756061 T AT 05756061T AT E519762 T1 ATE519762 T1 AT E519762T1
- Authority
- AT
- Austria
- Prior art keywords
- dopamine
- affinity
- receptor
- benzazepine compounds
- compounds
- Prior art date
Links
- 102000004073 Dopamine D3 Receptors Human genes 0.000 title 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 title 1
- 150000008038 benzoazepines Chemical class 0.000 title 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 125000004070 6 membered heterocyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0412314.7A GB0412314D0 (en) | 2004-06-02 | 2004-06-02 | Compounds |
| PCT/EP2005/005965 WO2005118549A2 (en) | 2004-06-02 | 2005-05-31 | Compounds having affinity for dopamine d3 receptor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE519762T1 true ATE519762T1 (de) | 2011-08-15 |
Family
ID=32696544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05756061T ATE519762T1 (de) | 2004-06-02 | 2005-05-31 | Benzazepinverbindungen mit affinität für den dopamin-d3-rezeptor und deren verwendung |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7989444B2 (de) |
| EP (1) | EP1751163B1 (de) |
| JP (1) | JP4890446B2 (de) |
| AT (1) | ATE519762T1 (de) |
| ES (1) | ES2371053T3 (de) |
| GB (1) | GB0412314D0 (de) |
| WO (1) | WO2005118549A2 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201031661A (en) * | 2009-02-17 | 2010-09-01 | Targacept Inc | Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands |
| GB0910674D0 (en) | 2009-06-19 | 2009-08-05 | Glaxo Group Ltd | Novel compounds |
| US20110269744A1 (en) | 2010-03-12 | 2011-11-03 | Astellas Pharma Inc. | Benzazepine Compound |
| US12215572B2 (en) | 2010-12-21 | 2025-02-04 | Fastcap Ultracapacitors Llc | Power system for high temperature applications with rechargeable energy storage |
| CN104271880A (zh) | 2011-05-24 | 2015-01-07 | 快帽系统公司 | 用于高温应用的具有可再充电能量存储器的电力系统 |
| US9558894B2 (en) | 2011-07-08 | 2017-01-31 | Fastcap Systems Corporation | Advanced electrolyte systems and their use in energy storage devices |
| WO2013009720A2 (en) | 2011-07-08 | 2013-01-17 | Fastcap Systems Corporation | High temperature energy storage device |
| CN108868747A (zh) | 2011-11-03 | 2018-11-23 | 快帽系统公司 | 生产测井仪 |
| FR3003859B1 (fr) * | 2013-03-26 | 2015-03-13 | Servier Lab | "procede de synthese de derives de la 7,8-dimethoxy-1,3-dihydro-2h-3-benzazepin-2-one et application a la synthese de l'ivabradine" |
| US10872737B2 (en) | 2013-10-09 | 2020-12-22 | Fastcap Systems Corporation | Advanced electrolytes for high temperature energy storage device |
| EP3084481B8 (de) | 2013-12-20 | 2024-01-03 | Fastcap Systems Corporation | Vorrichtung zur elektromagnetischen telemetrie |
| KR102668693B1 (ko) | 2015-01-27 | 2024-05-27 | 패스트캡 시스템즈 코포레이션 | 넓은 온도 범위 울트라커패시터 |
| CA3011201C (en) | 2016-01-15 | 2020-09-22 | Pfizer Inc. | 6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands |
| EP3549148B1 (de) | 2016-12-02 | 2025-01-01 | Fastcap Systems Corporation | Verbundelektrode |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4160765A (en) * | 1976-11-17 | 1979-07-10 | Smithkline Corporation | Method for 6-bromination of 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine compounds |
| DK26793D0 (da) * | 1993-03-10 | 1993-03-10 | Novo Nordisk As | Benzofuranyl- eller dihydrobenzofuranyl-substituerede tricycliske benzazepiner, der anvendelse og fremstilling |
| TWI274750B (en) | 1999-01-12 | 2007-03-01 | Abbott Gmbh & Co Kg | Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same |
| EP1335915B1 (de) * | 2000-11-14 | 2008-01-02 | Smithkline Beecham Plc | Tetrahydrobenzazepin-derivate zur verwendung als dopamin-d3-rezeptor-modulatoren (antipsychotische mittel) |
-
2004
- 2004-06-02 GB GBGB0412314.7A patent/GB0412314D0/en not_active Ceased
-
2005
- 2005-05-31 AT AT05756061T patent/ATE519762T1/de not_active IP Right Cessation
- 2005-05-31 ES ES05756061T patent/ES2371053T3/es not_active Expired - Lifetime
- 2005-05-31 US US11/569,880 patent/US7989444B2/en not_active Expired - Fee Related
- 2005-05-31 EP EP05756061A patent/EP1751163B1/de not_active Expired - Lifetime
- 2005-05-31 JP JP2007513858A patent/JP4890446B2/ja not_active Expired - Fee Related
- 2005-05-31 WO PCT/EP2005/005965 patent/WO2005118549A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005118549A2 (en) | 2005-12-15 |
| WO2005118549A3 (en) | 2006-04-13 |
| EP1751163B1 (de) | 2011-08-10 |
| GB0412314D0 (en) | 2004-07-07 |
| JP2008501660A (ja) | 2008-01-24 |
| EP1751163A2 (de) | 2007-02-14 |
| JP4890446B2 (ja) | 2012-03-07 |
| US20100016287A1 (en) | 2010-01-21 |
| US7989444B2 (en) | 2011-08-02 |
| ES2371053T3 (es) | 2011-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE483706T1 (de) | Weitere heteropolycyclische verbindungen und deren verwendung als antagonisten des metabotropen glutamatrezeptors | |
| ATE519762T1 (de) | Benzazepinverbindungen mit affinität für den dopamin-d3-rezeptor und deren verwendung | |
| ATE407938T1 (de) | Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür | |
| NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
| ATE542816T1 (de) | Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors | |
| CY1111206T1 (el) | Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων | |
| MX2007014400A (es) | Novedosos compuestos heterociclicos como moduladores aloestericos positivos de los receptores de glutamato metabotropicos. | |
| ATE536344T1 (de) | Histamine h3 receptor antagonisten | |
| BR0314059A (pt) | Compostos heterocìclicos | |
| NO20032161L (no) | Tetrahydrobenzazepinderivater for anvendelse som modulatorer av dopamine D3-reseptor (antipsykotiske midler) | |
| NZ595571A (en) | Pyrazole compounds and uses thereof | |
| WO2008056259A3 (en) | Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors | |
| CY1114382T1 (el) | 2-κυανοφαινυλ συντηγμενες ετεροκυκλικες ενωσεις, και συνθεσεις και χρησεις αυτων | |
| PL1620425T3 (pl) | Podstawione 3-cyjanotiofenoacetamidy jako antagoniści receptora glukagonu | |
| IL186777A0 (en) | (3,4-dihydro-quinazolin-2-yl) - (2-aryloxy-ethyl) - amines having an activity on the 5 - ht receptor | |
| TW200621753A (en) | Pyrimidinylimidazoles and methods of making and using the same | |
| TW200736255A (en) | 5-(Substituted)-pyrazolopiperidines | |
| IL202236A0 (en) | Prolinamide derivatives as nk3 antagonists | |
| DE602005019241D1 (de) | Heterocyclische kondensierte verbindungen und ihre verwendung als antidiuretische mittel | |
| ATE400553T1 (de) | 3,6-disubstituierte azabicyclo 3.1.0 - hexanderivative als antagonisten des muscarinrezeptors | |
| ATE478856T1 (de) | Spirobenzodioxole und deren verwendung als cb1- antagonisten | |
| NO20082214L (no) | 1,1-Diokso-tiomorfolinyl-indolyl-metanonderivater for anvendelse som H3-modulatorer | |
| ATE486071T1 (de) | Azabicycloä3.1.0ühexan-derivate als modulatoren des dopamin-d3-rezeptors | |
| ATE524451T1 (de) | Substituierte n-benzo ädü isoxazol-3-yl-amin- derivative als inhibitoren von mglur5, serotonin- (5-ht) und noradrenalin rezeptoren und deren verwendung zur herstellung von arzneimitteln | |
| DE602007012531D1 (de) | Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |